Overcoming Acquired PD-1/PD-L1 Resistance with CD38 Blockade

Cancer Discov. 2018 Sep;8(9):1066-1068. doi: 10.1158/2159-8290.CD-18-0798.


Overexpression of CD38 after PD-1/PD-L1 blockade increases extracellular adenosine levels and may contribute to acquired resistance to anti-PD-1/PD-L1 therapy. Cancer Discov; 8(9); 1066-8. ©2018 AACRSee related article by Chen et al., p. 1156.

Publication types

  • Comment

MeSH terms

  • B7-H1 Antigen*
  • Programmed Cell Death 1 Receptor*


  • B7-H1 Antigen
  • Programmed Cell Death 1 Receptor